SEER Inquiry System - Home
Welcome to the SEER Inquiry System (SINQ). SINQ is a collection of questions that cancer registrars have had while coding cancer cases. Click Search to look for specific questions or to select questions for a Report.
|Add to Report||ID||Question||Status||Last Updated|
|20130030||Histology--Heme & Lymphoid Neoplasms: In our database we have a patient diagnosed with 9684/3, Diffuse Large B-Cell Lymphoma (DLBCL), immunoblastic, in 2009. His 2010 recurrence at another hospital was called plasmablastic lymphoma and coded to 9735/3 per the 2010 Hemato database. I would like to know which code you would like to see on the merged records? Since 9684/3 is now listed as 'obsolete' I would prefer to use 9735/3. Do you agree that 9735/3 is the better code for the merged tumor record? Thanks.||Final||May 02 2013|
|20130029||Reportability--Heme & Lymphoid Neoplasms: Not sure if this should be registered or not, please advise.
Bone marrow: post polycythemic myelofibrosis
JAK2 mutations present confirming diagnosis of post polycythemic myelofibrosis. Patient does have history of polycythemia vera (PV). If this is to be registered what histology code?
|Final||May 02 2013|
|20130021||Histology/Grade--Heme & Lymphoid Neoplasms: Why is the classification change not explained in the hematopoietic database abstractor notes for follicular lymphoma (FL) (grade 1, 2, or 3)? If grade 1 is not being seperated from grade 2 and any FL with even a few centroblasts is being labelled as such, when will grade 1 be used on it's own? See discussion.||Final||Apr 26 2013|
|20130020||Reportability--Heme & Lymphoid Neoplasms: We have two 2013 cases with the diagnosis of aplastic anemia - which does not come up in the Hematopoietic database. Is it an alternative name for refractory anemia? Is it reportable?||Final||Apr 26 2013|
|20130019||Primary site--Heme & Lymphoid Neoplasms: When a patient has a positive lymph node biopsy and peripheral blood for B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, but refuses bone marrow biopsy, what is the primary site? Rule PH8 is confusing to me because this actually fits both bulleted statements. I am leaning toward C421, but can you please confirm?||Final||Apr 26 2013|
|20130018||Reportability--Heme & Lymphoid Neoplasms: If a patient has a diagnosis of 'thrombocytosis' or 'thrombocythemia,' it is NOT reportable unless it states 'essential or malignant' -- Correct?
I've recently been assigned to do all hematopoetic cases for my hospital system and I want to be sure this is correct. We see a lot of 'thrombocythemia' but I don't often see any stated as 'essential thrombocythemia.'
|Final||Apr 26 2013|
|20130017||Reportability--Heme & Lymphoid Neoplasms: Is reactive thrombocytosis reportable? See discussion.||Final||Apr 26 2013|
|20130015||Reportability--Heme & Lymphoid Neoplasms: I have seen an increase in the coding of essential thrombocytopenia. Many times it has been coded based on blood counts. I have also seen discharge summaries that say thrombocytosis and they get coded to essential thrombocytopenia. I need clarification on which cases should be reported.||Final||Apr 26 2013|
|20130014||Reportability-Heme & Lymphoid Neoplams: Is Castleman disease reportable 2010 and later? When you type it in the Hematopoietic Database, it states that it is reportable - 9738/3, but when I researched it online, it states that Castleman disease is a very rare disorder characterized by non-cancerous growths (tumors).||Final||Apr 26 2013|
|20130013||Reportability-Heme & Lymphoid Neoplasms: Is Mast Cell Activation Syndrome(MCAS)reportable? Our coders are giving it an ICD-9 code of 202.60, but the doctors say in the progress note that it is not the same as systemic mastocytosis. I can't find a listing for MCAS in the Hematopoietic and Lymphoid Database.||Final||Apr 26 2013|